Biblio
Export 561 results:
Author Title Type [ Year] Filters: First Letter Of Keyword is D [Clear All Filters]
“The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1195-1204, 2022.
, “Environmental Enrichment Effects on the Brain-Derived Neurotrophic Factor Expression in Healthy Condition, Alzheimer's Disease, and Other Neurodegenerative Disorders.”, J Alzheimers Dis, vol. 85, no. 3, pp. 975-992, 2022.
, “Functional Neurophysiological Biomarkers of Early-Stage Alzheimer's Disease: A Perspective of Network Hyperexcitability in Disease Progression.”, J Alzheimers Dis, vol. 88, no. 3, pp. 809-836, 2022.
, “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
, “Informal Caregivers' Attitude Toward Dementia: The Impact of Dementia Knowledge, Confidence in Dementia Care, and the Behavioral and Psychological Symptoms of the Person with Dementia. A Cross-Sectional Study.”, J Alzheimers Dis, vol. 88, no. 3, pp. 971-984, 2022.
, “Interaction Between Diet and Microbiota in the Pathophysiology of Alzheimer's Disease: Focus on Polyphenols and Dietary Fibers.”, J Alzheimers Dis, vol. 86, no. 3, pp. 961-982, 2022.
, “Interaction Between Diet and Microbiota in the Pathophysiology of Alzheimer's Disease: Focus on Polyphenols and Dietary Fibers.”, J Alzheimers Dis, vol. 86, no. 3, pp. 961-982, 2022.
, “Interaction Between Diet and Microbiota in the Pathophysiology of Alzheimer's Disease: Focus on Polyphenols and Dietary Fibers.”, J Alzheimers Dis, vol. 86, no. 3, pp. 961-982, 2022.
, “Probiotic Bifidobacterium breve Prevents Memory Impairment Through the Reduction of Both Amyloid-β Production and Microglia Activation in APP Knock-In Mouse.”, J Alzheimers Dis, vol. 85, no. 4, pp. 1555-1571, 2022.
, “Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1203-1228, 2022.
, “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
, “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
, “Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model.”, J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
, “A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 485-501, 2022.
, “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
, “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
, “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
, “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.
, “APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 79, no. 2, pp. 511-530, 2021.
, “Assessing the Progression of Alzheimer's Disease in Real-World Settings in Three European Countries.”, J Alzheimers Dis, vol. 80, no. 2, pp. 749-759, 2021.
, “Automatic Subtyping of Individuals with Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1185-1194, 2021.
, “The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation.”, J Alzheimers Dis, vol. 81, no. 4, pp. 1505-1527, 2021.
, “The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation.”, J Alzheimers Dis, vol. 81, no. 4, pp. 1505-1527, 2021.
, “Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches.”, J Alzheimers Dis, vol. 79, no. 3, pp. 931-948, 2021.
, “Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 80, no. 3, pp. 973-977, 2021.
,